These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35147696)

  • 21. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
    Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
    Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.
    Wu MZ; Teng TK; Tsang CT; Chan YH; Lee CH; Ren QW; Huang JY; Cheang IF; Tse YK; Li XL; Xu X; Tse HF; Lam CSP; Yiu KH
    Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):45-52. PubMed ID: 37942588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
    Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
    Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database.
    Subramanian A; Gokhale K; Sainsbury C; Nirantharakumar K; Toulis KA
    Diabetes Obes Metab; 2023 Jan; 25(1):156-165. PubMed ID: 36056476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Cowan A; Jeyakumar N; Kang Y; Dixon SN; Garg AX; Naylor K; Weir MA; Clemens KK
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):835-842. PubMed ID: 35618342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.
    Abrahami D; Tesfaye H; Yin H; Vine S; Hicks B; Yu OHY; Campeau L; Platt RW; Schneeweiss S; Patorno E; Azoulay L
    Diabetes Care; 2022 Dec; 45(12):2907-2917. PubMed ID: 36170656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Diabet Med; 2022 Aug; 39(8):e14858. PubMed ID: 35460294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.
    Cesta CE; Rotem R; Bateman BT; Chodick G; Cohen JM; Furu K; Gissler M; Huybrechts KF; Kjerpeseth LJ; Leinonen MK; Pazzagli L; Zoega H; Seely EW; Patorno E; Hernández-Díaz S
    JAMA Intern Med; 2024 Feb; 184(2):144-152. PubMed ID: 38079178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
    Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jørgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomäki J; Karasik A; Goh SY; Chiang CE; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P; Kosiborod M;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):606-615. PubMed ID: 32559476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study.
    Sarma S; Hodzic-Santor B; Raissi A; Colacci M; Verma AA; Razak F; Højbjerg Lassen MC; Fralick M
    J Diabetes Complications; 2024 Sep; 38(9):108827. PubMed ID: 39096768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
    Jeon JY; Ha KH; Kim DJ
    Diabetes Metab J; 2021 Jul; 45(4):505-514. PubMed ID: 33120439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.
    Pradhan R; Yu OHY; Platt RW; Azoulay L
    BMJ Open Diabetes Res Care; 2023 Nov; 11(6):. PubMed ID: 37949470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
    Sung HL; Hung CY; Tung YC; Lin CC; Tsai TH; Huang KH
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
    Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.
    Wu MZ; Chandramouli C; Wong PF; Chan YH; Li HL; Yu SY; Tse YK; Ren QW; Yu SY; Tse HF; Lam CSP; Yiu KH
    Diabetes Metab; 2022 Nov; 48(6):101367. PubMed ID: 35753654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema.
    Phu A; Banghart M; Bahrainian M; Liu TYA; Wolf RM; Channa R
    J Diabetes Complications; 2024 Aug; 38(8):108808. PubMed ID: 39018897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.